J&J Seeks To Block Generic Topamax
Johnson & Johnson’s preliminary injunction request, filed Thursday, came a month after the U.S. Food and Drug Administration cleared the way for Mylan Laboratories Inc. to sell Topiramate tablets in three dosage strengths—25 mg, 100 mg and 200 mg.
Topamax, which is covered by patents set to expire in 2008, boasts combined annual sales of approximately $1.4 billion for Johnson & Johnson....
Already a subscriber? Click here to login